


EQAS Alert: Decoding BC-720's Platelet Outliers

Jithin Preetha



CONTENTS

01. Case Background



02. Case Ideas



03. Case Solution



04. Case Summary



Case Background

Background

Ideas

Solution

Summary

- Customer have enrolled Mindray BC-720 Analyzer in EQA Survey of ISHTM-AIIMS .
- Customer feedback: For First EQA results show precision testing (within lab) is satisfactory for PLT, but **PLT parameters are showing outlier** in accuracy testing (among lab)

Problem & Customer request:

What caused the EQA results of PLT parameters outlier and how to solve this?

Case Background

Background

Ideas

Solution

Summary

Page 1 of 2

ISHTM **ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME**
NABL accredited program as per ISO/IEC 17043:2023 standard
Organized By Department of Hematology, AIIMS, New Delhi-110029

Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No. : 2501 Distribution No.: 167-E Month/Year: March/2025
Instrument ID: Mindray Model Name.: 720 Serial No.: BC 720

Date of issue & status of the report: 14-05-2025 [Final]

CBC and Retic Assessment

Test Parameters	S.No.	Among Lab (Accuracy Testing)					Within Lab (Precision Testing)				
		Your Result 1	Your Result 2	Your Results Sum of 2 Value	Consensus result sum of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score	Yours Results Diff. of 2 Values	Consensus Result Diff. of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score
WBC x10 ⁹ /µl	1	11.09	10.89	21.98	20.73	0.116	0.37	0.2	0.19	0.012	0.06
RBC x10 ⁶ /µl	1	4.27	4.24	8.51	8.31	0.011	0.59	0.03	0.03	0.002	-0.13
Hb g/dl	1	11.5	11.5	23	22.4	0.033	0.58	0	0.1	0.007	-1.35
HCT%	1	39.3	39.1	78.4	71.8	0.198	1.12	0.2	0.3	0.021	-0.27
MCV-fl	1	92.1	92.1	184.2	172.45	0.389	0.97	0	0.2	0.020	-0.64
MCH-Pg	1	27.1	26.9	54	54.1	0.056	-0.07	0.2	0.2	0.013	0.00
MCHC-g/dl	1	29.4	29.2	58.6	62.7	0.167	-0.81	0.2	0.3	0.018	-0.34
Plt. x10 ⁹ /µl	1	264	256	520	249	3.067	3.22	8	5	0.335	0.51
Retic %	2	3.41	3.21	6.62	13	0.174	-1.23	0.2	0.5	0.032	-0.51

P.S. Assessment

YOUR REPORT		CONSENSUS REPORT
DLC%	Nrbc=01, Poly=27 L=58, E=02, Mono/Promono=09, B1=01 P.M.=02, Mye=01, Meta=0, Other=0	Lymp: 46-81, Poly: 20-30, Mono: 2-6, Eosino: 1-2, nRBC/blast/Promyelo/Myelo/Meta: 0-5
RBC Morphology	NORMOCYTIC HYPOCHROMIC NORMOCYTIC NORMOCHROMIC POLYCHROMATIC CELLS, FEW MICROCYTES MACROVALOCYTES, TARGET CELLS	Normocytic, normochromic to macrocytic; polychromatophils seen.
Diagnosis	CHRONIC LYMPHOPROLIFERATIVE DISORDER.. THE POSSIBILITY OF HAIRY CELL LEUKAEMIA TO BE CONSIDERED. ADVISED IMMUNOPHENOTYPING	Chronic Lymphoproliferative Disorder (CLPD)

- ✓ The Result reported by Lab for PLT : 520 x10³
- ✓ Peer Group Assigned Values for PLT : 249 x10³
- ✓ Among Lab EQA : Z Score : 3.22 : **Rejected**
- ✓ With in Lab EQA : Z Score : 0.51 : **Acceptable**

Z-Score Criteria as per EQAS

Z Score	Results
Between 0 to +-2.0	Results acceptable
Between +-2 to +- 2.5	Warning
Above +-2.5	Result unacceptable

- EQAS Report verified observed PLT parameters are showing outlier in Accuracy testing (among lab).
- Precision testing (within lab) is satisfactory for PLT.
- While the other EQAS parameters with in acceptable.
- Observed IQC and Patients results no issues observed

Troubleshooting


Background

Ideas

Solution


Summary

What reasons will cause:



Troubleshooting

What has been verified:



Troubleshooting

Background

Ideas

Solution

Summary

Checked Original Test Results:

- Verified and Observed customer processed EQAS Samples in **CD Mode** in BC-720 is it correct mode **to process EQAS Sample** ?
- In CD Mode PLT-I & PLT-H will be measured and default PLT results released is PLT-H.
- Is there any values difference for PLT-I & PLT-H for EQAS samples ?
- AIIMS EQAP not defined peer group for PLT-H –Wrong Peer Group Comparison ?

Hematology Analysis Report					
Last Name:		Sample ID: AIIM 167-E 1			
Age:		Patient ID:			
Bed No.:		Date of Analysis: 26-03-2025 13:4			
No.:		Ward:			
Diagnosis:		Tube Pos.:			
OV-WB-CD					
Date of Birth:					
Para.		Result Unit	Ref. Ranges	Flag	
1 WBC	& H	10.89 10 ³ /uL	4.00 - 10.00	Blasts?	
2 Neu#	& RH	7.03 10 ³ /uL	2.00 - 7.00	Immature Gran?	
3 Lym#	& R	2.95 10 ³ /uL	0.80 - 4.00	Left Shift?	
4 Mon#	R	0.70 10 ³ /uL	0.12 - 1.20	PLT Clump?	
5 Eos#	R	0.20 10 ³ /uL	0.02 - 0.50	PLT Histogram Abn.	
6 Bas#	R	0.01 10 ³ /uL	0.00 - 0.10	PLT-H Histogram Abn.	
7 IMG#	R	0.60 10 ³ /uL	0.00 - 999.99		
8 Neu%	& R	64.6 %	50.0 - 70.0		
9 Lym%	& R	27.1 %	20.0 - 40.0		
10 Mon%	R	6.4 %	3.0 - 12.0		
11 Eos%	R	1.8 %	0.5 - 5.0		
12 Bas%	R	0.1 %	0.0 - 1.0		
13 IMG%	R	5.5 %	0.0 - 100.0		
14 RBC		4.24 10 ⁶ /uL	3.50 - 5.50		
15 HGB		11.5 g/dL	11.0 - 16.0		
16 HCT		39.1 %	37.0 - 54.0		
17 MCV		92.1 fL	80.0 - 100.0		
18 MCH		27.1 pg	27.0 - 34.0		
19 MCHC	L	29.4 g/dL	32.0 - 36.0		
20 RDW-CV	H	18.0 %	11.0 - 16.0		
21 RDW-SD	H	49.2 fL	35.0 - 56.0		
22 PLT	& R	264 10 ³ /uL	100 - 300		
23 PLT-I	R	123 10 ³ /uL	100 - 300		
24 PLT-H	R	264 10 ³ /uL	100 - 300		
25 MPV	RH	16.1 fL	6.5 - 12.0		
26 PDW	R	16.9	15.0 - 17.0		
27 PCT	R	0.198 %	0.108 - 0.282		
28 P-LCC	RH	190 10 ⁹ /L	30 - 90		
29 P-LCR	RH	71.8 %	11.0 - 45.0		
30 IPF	RH	43.4 %	0.9 - 10.0		
31 NRBC#		0.027 10 ³ /uL	0.000 - 9999.999		
32 NRBC%		0.24 /100WBC	0.00 - 9999.99		

Hematology Analysis Report					
Last Name:		Sample ID: AIIM 167-E 11			
Age:		Patient ID:			
Bed No.:		Date of Analysis: 26-03-2025 13:51			
No.:		Ward:			
Diagnosis:		Tube Pos.:			
OV-WB-CD					
Date of Birth:					
Para.		Result Unit	Ref. Ranges	Flag	
1 WBC	& H	11.09 10 ³ /uL	4.00 - 10.00	Blasts?	
2 Neu#	& RH	7.03 10 ³ /uL	2.00 - 7.00	Abn Lymph/blast?	
3 Lym#	& R	3.10 10 ³ /uL	0.80 - 4.00	Immature Gran?	
4 Mon#	R	0.73 10 ³ /uL	0.12 - 1.20	Left Shift?	
5 Eos#	R	0.21 10 ³ /uL	0.02 - 0.50	PLT Clump?	
6 Bas#	R	0.02 10 ³ /uL	0.00 - 0.10	PLT Histogram Abn.	
7 IMG#	R	0.58 10 ³ /uL	0.00 - 999.99	PLT-H Histogram Abn.	
8 Neu%	& R	63.3 %	50.0 - 70.0		
9 Lym%	& R	28.0 %	20.0 - 40.0		
10 Mon%	R	6.6 %	3.0 - 12.0		
11 Eos%	R	1.9 %	0.5 - 5.0		
12 Bas%	R	0.2 %	0.0 - 1.0		
13 IMG%	R	5.2 %	0.0 - 100.0		
14 RBC		4.27 10 ⁶ /uL	3.50 - 5.50		
15 HGB		11.5 g/dL	11.0 - 16.0		
16 HCT		39.3 %	37.0 - 54.0		
17 MCV		92.1 fL	80.0 - 100.0		
18 MCH	L	26.9 pg	27.0 - 34.0		
19 MCHC	L	29.2 g/dL	32.0 - 36.0		
20 RDW-CV	H	18.0 %	11.0 - 16.0		
21 RDW-SD	H	59.0 fL	35.0 - 56.0		
22 PLT	& R	256 10 ³ /uL	100 - 300		
23 PLT-I	R	117 10 ³ /uL	100 - 300		
24 PLT-H	R	256 10 ³ /uL	100 - 300		
25 MPV	RH	10.0 fL	6.5 - 12.0		
26 PDW	R	16.7	15.0 - 17.0		
27 PCT	R	0.194 %	0.108 - 0.282		
28 P-LCC	RH	190 10 ⁹ /L	30 - 90		
29 P-LCR	RH	74.2 %	11.0 - 45.0		
30 IPF	RH	45.0 %	0.9 - 10.0		
31 NRBC#		0.037 10 ³ /uL	0.000 - 9999.999		
32 NRBC%		0.33 /100WBC	0.00 - 9999.99		

Case Solution

Background

Ideas

Solution

Summary

EQAS REPORT : 1

Hematology Analysis Report				
Last Name:		Sample ID: AIIM 167-E 1		
Age:		Patient ID:		
Bed No.:		Date of Analysis: 26-03-2025 13:4		
Ward:		Tube Pos.:		
No.:		Date of Birth:		
Diagnosis:				
Para.		Result Unit	Ref. Ranges	Flag
1 WBC	& H	10.89 10 ³ /uL	4.00 - 10.00	Blasts?
2 Neu#	& RH	7.03 10 ³ /uL	2.00 - 7.00	Immature Gran?
3 Lym#	& R	2.95 10 ³ /uL	0.80 - 4.00	Left Shift?
4 Mon#	R	0.70 10 ³ /uL	0.12 - 1.20	PLT Clump?
5 Eos#	R	0.20 10 ³ /uL	0.02 - 0.50	PLT Histogram Abn.
6 Bas#	R	0.01 10 ³ /uL	0.00 - 0.10	PLT-H Histogram Abn.
7 IMG#	R	0.60 10 ³ /uL	0.00 - 999.99	
8 Neu%	& R	64.6 %	50.0 - 70.0	
9 Lym%	& R	27.1 %	20.0 - 40.0	
10 Mon%	R	6.4 %	3.0 - 12.0	
11 Eos%	R	1.8 %	0.5 - 5.0	
12 Bas%	R	0.1 %	0.0 - 1.0	
13 IMG%	R	5.5 %	0.0 - 100.0	
14 RBC		4.24 10 ⁶ /uL	3.50 - 5.50	
15 HGB		11.5 g/dL	11.0 - 16.0	
16 HCT		39.1 %	37.0 - 54.0	
17 MCV		92.1 fL	80.0 - 100.0	
18 MCH		27.1 pg	27.0 - 34.0	
19 MCHC	L	29.4 g/dL	32.0 - 36.0	
20 RDW-CV	H	18.0 %	11.0 - 16.0	
21 RDW-SD	H	60.2 fL	35.0 - 56.0	
22 PLT	& R	264 10 ³ /uL	100 - 300	
23 PLT-I	R	123 10 ⁹ /L	100 - 300	
24 PLT-H	R	264 10 ⁹ /L	100 - 300	
25 MPV	RH	16.1 fL	6.5 - 12.0	
26 PDW	R	16.9	15.0 - 17.0	
27 PCT	R	0.198 %	0.108 - 0.282	
28 P-LCC	RH	190 10 ⁹ /L	30 - 90	
29 P-LCR	RH	71.8 %	11.0 - 45.0	
30 IPF	RH	43.4 %	0.9 - 10.0	
31 NRBC#		0.027 10 ³ /uL	0.000 - 9999.999	
32 NRBC%		0.24 /100WBC	0.00 - 9999.99	

EQAS REPORT : 2

Hematology Analysis Report				
Last Name:		Sample ID: AIIM 167-E 11		
Age:		Patient ID:		
Bed No.:		Date of Analysis: 26-03-2025 13:51		
Ward:		Tube Pos.:		
No. [redacted]		Date of Birth:		
Diagnosis:				
Para.		Result Unit	Ref. Ranges	Flag
1 WBC	& H	11.09 10 ³ /uL	4.00 - 10.00	Blasts?
2 Neu#	& RH	7.03 10 ³ /uL	2.00 - 7.00	Abn Lymph/blast?
3 Lym#	& R	3.10 10 ³ /uL	0.80 - 4.00	Immature Gran?
4 Mon#	R	0.73 10 ³ /uL	0.12 - 1.20	Left Shift?
5 Eos#	R	0.21 10 ³ /uL	0.02 - 0.50	PLT Clump?
6 Bas#	R	0.02 10 ³ /uL	0.00 - 0.10	PLT Histogram Abn.
7 IMG#	R	0.58 10 ³ /uL	0.00 - 999.99	PLT-H Histogram Abn.
8 Neu%	& R	63.3 %	50.0 - 70.0	
9 Lym%	& R	28.0 %	20.0 - 40.0	
10 Mon%	R	6.6 %	3.0 - 12.0	
11 Eos%	R	1.9 %	0.5 - 5.0	
12 Bas%	R	0.2 %	0.0 - 1.0	
13 IMG%	R	5.2 %	0.0 - 100.0	
14 RBC		4.27 10 ⁶ /uL	3.50 - 5.50	
15 HGB		11.5 g/dL	11.0 - 16.0	
16 HCT		39.3 %	37.0 - 54.0	
17 MCV		92.1 fL	80.0 - 100.0	
18 MCH	L	26.9 pg	27.0 - 34.0	
19 MCHC	L	29.2 g/dL	32.0 - 36.0	
20 RDW-CV	H	18.0 %	11.0 - 16.0	
21 RDW-SD	H	59.0 fL	35.0 - 56.0	
22 PLT	& R	256 10 ³ /uL	100 - 300	
23 PLT-I	R	117 10 ⁹ /L	100 - 300	
24 PLT-H	R	256 10 ⁹ /L	100 - 300	
25 MPV	RH	16.6 fL	6.5 - 12.0	
26 PDW	R	16.7	15.0 - 17.0	
27 PCT	R	0.194 %	0.108 - 0.282	
28 P-LCC	RH	190 10 ⁹ /L	30 - 90	
29 P-LCR	RH	74.2 %	11.0 - 45.0	
30 IPF	RH	45.0 %	0.9 - 10.0	
31 NRBC#		0.037 10 ³ /uL	0.000 - 9999.999	
32 NRBC%		0.33 /100WBC	0.00 - 9999.99	

AIMS EQAS SAMPLE -167 : Report -1

PLT-I : 123×10^3

PLT-H : 264×10^3

PLT : 264×10^3

AIMS EQAS SAMPLE -167 : Report -2

PLT-I : 117×10^3

PLT-H : 256×10^3

PLT : 256×10^3

Peer Group Mean Data : 249×10^3

PLT-I : $123 + 117 = 240 \times 10^3$


PLT-H : $264 + 256 = 520 \times 10^3$

Observation : Customer reported PLT-H Instead of PLT-I. The peer group comparison data is with PLT-I.


PLT-H: A new parameter for accurate platelet counting with anti-interference ability



Normal sample



Interference sample



RBC/PLT volume distribution histogram

PLT-I : In the traditional impedance method, PLTs are subject to interferences that may lead to falsely high or falsely low results, the large PLTs are interfered by microcytic RBCs and fragments, but the small ones are not.

PLT-H : From the DIFF channel, the RBCs are dissolved by reagents, the PLT structure remains intact, and large PLTs are detected by the precise optical methodology. By combining the small PLTs from the conventional impedance method and, the large ones from the optical method, an accurate PLT count will be obtained.

PLT-H in every CD tests

Background


Ideas

Solution


Summary

IMPEDANCE METHOD

Normal Sample



Abnormal Sample



False High

Small RBC
Fragmented RBC

Bleeding
(without timely
intervention)


False Low

Large PLT
PLT Clumps

Unnecessarily blood
transfusion /
high risk of infection


MINDRAY PLT-H

Impedance Channel




Detection of Small
PLT by Impedance
Method


Optical Channel



Detection of Large
PLT by DIFF Channel



MERGE



Information from
dual channels
integrated into
Hybrid Channel PLT-
H

Troubleshooting

Background





Ideas

Solution

Summary

Why there is a difference between PLT-I and PLT-H in EQA Sample ?

- The most important property of the EQA sample is Commutability.
- A non-commutable EQA sample includes matrix related bias that occurs only in the EQA sample but not in authentic clinical patient Samples.
- Matrix relate bias is due to an unwanted distortion of the test result attributed to physical and chemical differences in the samples
- As EQAS is not true Blood sample it is Spiked / Artificially packed with cells, Tailored material, so SOP should be followed recommended by manufacture.



Reference : External Quality Assessment in Laboratory Medicine by Gunn Berit Berge Kristensen*1, Piet Meijer2

Case Solution

Background

Ideas

Solution

Summary

Sample ID: EQAS ②

Sample Mode: WB ③

Test Panel: CD, CDR, CD+ESR, CDR+ESR, CBC, Other Mode ④

Other Mode: CBC ⑤

Sequence ⑥

Proposed solutions for this Case:

- ✓ Always Run EQA sample in CBC Mode for **AIIMS-EQA**
- ✓ All parameters in EQAP Scops cover under CBC Mode
- ✓ In CBC Mode PLT-I & CD Mode PLT-I & PLT-H –Default PLT-H released.
- ✓ Customer understood the problem and informed they will Run EQA in CBC Mode.

Tips: If there is no specified testing mode for other EQA projects, it is also possible to consider using quality control mode, as only PLT-I reports are used for PLT testing in quality control mode.

AIMS EQAS SAMPLE -168B - E: June/2025

- Latest result obtained for the Latest EQA sample (168B) had been found to be well within range.
- Performance of both Accuracy (Among Lab) and Precision (Within Lab) had been found satisfactory for PLT.
- Z score for PLT Indices – 0.32

Page 2 of 2

Page 1 of 2

COMBINED DATA VALUES OF TOTAL PARTICIPANTS

Test parameters	S.No.	Total participants covered in the current dist. 168-E	Total No. responded	% of Labs with Z Score 0-2		% of Labs with Z Score 2-3		% of Labs with Z Score >3	
				Among labs	Within lab	Among labs	Within lab	Among labs	Within lab
WBC x10 ⁹ /μl	1	368	367	81.47	82.83	3.54	5.45	14.990	11.72
RBC x10 ¹² /μl	1	368	368	90.76	92.93	6.25	2.17	2.99	4.9
Hb g/dl	1	368	368	90.22	89.95	5.16	4.35	4.62	5.7
HCT%	1	368	367	85.83	89.37	9.26	5.18	4.91	5.45
MCV-fL	1	368	366	89.07	90.16	7.1	4.37	3.83	5.47
MCH-Pg	1	368	366	86.61	92.35	8.47	2.19	4.92	5.46
MCHC-g/dl	1	368	366	92.35	87.98	4.1	3.28	3.55	8.74
Plt. x10 ¹² /μl	1	368	368	88.04	92.66	4.35	3.53	7.61	3.81
Retic Count%	2	368	315	95.56	91.75	4.13	2.86	0.31	5.39
Assessment	1	368	319	Satisfactory :92.93%, Borderline Sat. :1.63%, Unsatisfactory :5.44%					

Comments:

1). Among Lab (EQA) : Results acceptable.

2). Within Lab (IQA) : Precision acceptable.

Note-1: EQA (External Quality Assurance) - Your Performance among various of participating labs in PT, to determine the accuracy of your results.

IQA (Internal Quality Assurance) : Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

Note-2: Z score among & within lab were calculated, as per to ISO/IEC 13528:2022 standard. Z score among lab (EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR)

Z score within lab (IQA)= (Your Result Difference of two values - Consensus Result difference of two values)/(Normalised IQR)

IQR = Quartile 3 - Quartile 1 of participant data, Normalised IQR = 0.7413 x IQR

Note-3: Z score 0 to ±2: Acceptable, Z score ±2 to ±3: Warning Signal, Z score > ±3 : Unacceptable [As per ISO/IEC 13528:2022 standard]

Note-4: Z score value between "0 to ±2" are texted in green colour. Z score value between "±2 to ±3" are texted in orange colour. Z score value > ±3 are texted in red colour.

Note-5: Homogeneity and stability testing of PT sample were done as per ISO 13528:2022 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3*SDPA). To pass the stability test, average difference in measurement values of first and last day sample ($\bar{x}-\bar{y}$) should be smaller than the check value (0.3*SDPA).

Note-6: ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

Note-7: Participants are free to use methods/analyzer of their own choice.

Note-8: Proficiency testing (PT) samples are sent quarterly to each participant.

Note-9: All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website www.ishtmalimseqap.com.

Note 10: Reports are kept confidential.

Report authorized by,



Dr. Manoranjan Mahapatra (Prof. & Head)

PT Co-ordinator: ISHTM-AIIMS-EQAP

Department of Hematology, AIIMS, New Delhi

-----End Of Report-----





PROFICIENCY TESTING REPORT

ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME

NABL accredited program as per ISO/IEC 17043:2023 standard

Organized By Department of Hematology, AIIMS, New Delhi-110029



Duration of stability testing - minimum upto 8 days at ambient temp. After dispatch of specimens

EQAP CODE No.: 2501

Distribution No: 168-E

Month/Year: June/2025

Instrument ID: Mindray

Model Name: BC 720

Date of issue & status of the report: 25-08-2025 [Final]

CBC and Retic Assessment

Test Parameters	S.No.	Among Lab (Accuracy Testing)					Within Lab (Precision Testing)				
		Your Result	Your Result	Consensus result sum of 2 values	Uncertainty of Assigned Values	Z Score	Your Results Diff. of 2 Values	Consensus Result Diff. of 2 values	Uncertainty of Assigned Values	Z Score	
WBC x10 ⁹ /μl	1	5.61	5.51	11.12	10.04	0.035	1.22	0.1	0.1	0.007	0.00
RBC x10 ¹² /μl	1	4.61	4.49	9.1	9.21	0.010	-0.39	0.12	0.04	0.002	2.16
Hb g/dl	1	14.4	14.2	28.6	29.3	0.026	-0.86	0.21	0.1	0.007	0.71
HCT%	1	44.9	43.5	88.4	86.8	0.150	0.40	1.4	0.4	0.023	2.70
MCV-fL	1	97.4	96.9	194.3	188.7	0.280	0.76	0.5	0.25	0.020	0.67
MCH-Pg	1	31.6	31.2	62.8	63.5	0.065	-0.41	0.4	0.2	0.016	0.90
MCHC-g/dl	1	32.6	32	64.6	67.5	0.132	-0.73	0.6	0.3	0.018	1.01
Plt. x10 ¹² /μl	1	259	246	505	489	1.782	0.32	13	6	0.360	1.05
Retic %	2	2	1.9	3.9	6.8	0.140	-0.59	0.1	0.4	0.022	-0.67

Summary

Background

Ideas

Solution

Summary

- ✓ EQA Outliers Should Lead to Corrective Actions :



“Corrective Actions”: An action taken to correct a problem or deficiency

- ✓ Steps for Corrective Actions :



- ✓ PLT-H Results is more Accurate than PLT-I, Due to Matrix effect EQAS sample is not Compatible with PLT-H
- ✓ Guidance should be given to customer to Process EQAS in CBC mode to Avoid outliers.

THANK YOU

mindray迈瑞